Eli Lilly and Company
Compare market positioning with top industry peers
Explore Eli Lilly and
Core profile pages, annual revenue records, and related research hubs for this company.
Financial Performance
Revenue
$65.2B
Market Cap
$845.2B
Net Income
$20.6B
Employees
43,000
Eli Lilly's financial narrative is a story of absolutely unprecedented, explosive growth driven by a single class of drugs. Wall Street has completely revalued the company, pushing its market capitalization past massive tech companies. The financial mechanics are staggering: millions of Americans are desperate to pay roughly $1,000 a month for Zepbound (their weight-loss injection). The demand is so massive that the only constraint on their revenue is how fast they can physically manufacture the incredibly complex injector pens. They are generating massive, historic free cash flow.
Revenue Trend Analysis
YoY Change
+44.7%
4-Year CAGR
+23.2%
Peak Year
2025
Trend
Consistent Growth
Eli Lilly and Company has reported revenue across 5 fiscal years, compounding at +23.2% annually over 4 years. The most recent year saw a 44.7% increase versus the prior year. Revenue peaked in 2025 at $65.2B. Out of 4 reported periods, 4 showed growth and 0 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $65.2B | $20.6B | +44.7% |
| FY2024 | $45.0B | $10.6B | +32.0% |
| FY2023 | $34.1B | $5.2B | +19.6% |
| FY2022 | $28.5B | $6.2B | +0.8% |
| FY2021 | $28.3B | $5.6B | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Eli Lilly and Company reported approximately $48.5B in fiscal year 2025 with a team of 43,000 employees worldwide.
Eli Lilly and Company strategically balances reinvestment into core R&D with operational cost discipline, focusing on workflow automation to expand operating margins in 2026.
Financial performance in Pharmaceuticals, obesity medicines, diabetes care, oncology, immunology, and neuroscience is driven by steady cash generation and pricing power, enabling Eli Lilly and Company to reinvest in high-return strategic initiatives.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Eli Lilly and Company Revenue & Financials." CorpDigest, https://corpdigest.com/company/eli-lilly/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Eli Lilly and Company reported $65B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/eli-lilly/financials" target="_blank" rel="noopener">CorpDigest — Eli Lilly and Company financials</a></div>